Literature DB >> 29349812

Drug promotion practices: A review.

Nilan T Jacob1.   

Abstract

Over the years, the pharmaceutical industry has been at the forefront of research and innovation in drug discovery and development. The process of drug discovery extending from preclinical studies to multicentric clinical trials and postmarketing phase is a costly affair running into billions of dollars. On the flip side, not all investigational molecules clear the trial phases and get approved, which puts pressure on the manufacturers to maximize the profit from approved drugs. It is in this key area that the practice of drug promotion plays its role. The World Health Organization defines drug promotion as "all informational and persuasive activities by manufacturers and distributors, the effect of which is to influence the prescription, supply, purchase or use of medicinal drugs". With its humble intent of creating awareness among healthcare professionals and updating their knowledge on recent advances in treatment options, drug promotion has been an important tool, but gradually it has evolved to embrace aggressive marketing strategies and sometimes unethical business and scientific practices where the need for profit-making eclipses commitment to patient care and scientific exploration. In this review, we discuss the evolution of drug promotion practices, the various types, its merits and demerits, the influence of drug promotion on physician prescribing behaviour, the role of regulatory bodies, unethical promotional practices and finally summarize with future directions.
© 2018 The British Pharmacological Society.

Entities:  

Keywords:  drug promotion; medical marketing; pharmaceutical industry

Mesh:

Substances:

Year:  2018        PMID: 29349812      PMCID: PMC6046507          DOI: 10.1111/bcp.13513

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Separating continuing medical education from pharmaceutical marketing.

Authors:  A S Relman
Journal:  JAMA       Date:  2001-04-18       Impact factor: 56.272

2.  Selling sickness: the pharmaceutical industry and disease mongering.

Authors:  Ray Moynihan; Iona Heath; David Henry
Journal:  BMJ       Date:  2002-04-13

3.  Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?

Authors:  C Lee Ventola
Journal:  P T       Date:  2011-10

4.  The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.

Authors:  Gisela Schott; Henry Pachl; Ulrich Limbach; Ursula Gundert-Remy; Wolf-Dieter Ludwig; Klaus Lieb
Journal:  Dtsch Arztebl Int       Date:  2010-04-23       Impact factor: 5.594

5.  Should the drug industry work with key opinion leaders? Yes.

Authors:  Charlie Buckwell
Journal:  BMJ       Date:  2008-06-21

6.  Regulating off-label drug use--rethinking the role of the FDA.

Authors:  Randall S Stafford
Journal:  N Engl J Med       Date:  2008-04-03       Impact factor: 91.245

Review 7.  Drug promotion practices: A review.

Authors:  Nilan T Jacob
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

8.  An insight into the emerging role of regional medical advisor in the pharmaceutical industry.

Authors:  Sandeep Kumar Gupta; Roopa P Nayak
Journal:  Perspect Clin Res       Date:  2013-07

Review 9.  Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?

Authors:  Sergio Sismondo
Journal:  PLoS Med       Date:  2007-09       Impact factor: 11.069

10.  Differential Globalization of Industry- and Non-Industry-Sponsored Clinical Trials.

Authors:  Ignacio Atal; Ludovic Trinquart; Raphaël Porcher; Philippe Ravaud
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

View more
  9 in total

Review 1.  The British Pharmacological Society's WDM Paton Memorial Lecture 2019: How doctors were informed about pharmaceutical products through advertising in the British Medical Journal from 1955/6 to 1985/6.

Authors:  Jeffrey K Aronson; A Richard Green
Journal:  Br J Clin Pharmacol       Date:  2019-07-12       Impact factor: 4.335

Review 2.  Drug promotion practices: A review.

Authors:  Nilan T Jacob
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

3.  Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province.

Authors:  Moliehi Matlala; Andries G S Gous; Johanna C Meyer; Brian Godman
Journal:  Front Pharmacol       Date:  2020-08-18       Impact factor: 5.810

4.  Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan.

Authors:  Kana Yamamoto; Anju Murayama; Akihiko Ozaki; Hiroaki Saito; Toyoaki Sawano; Tetsuya Tanimoto
Journal:  Int Urogynecol J       Date:  2020-11-05       Impact factor: 2.894

5.  Perceptions of and barriers to ethical promotion of pharmaceuticals in Pakistan: perspectives of medical representatives and doctors.

Authors:  Rehan Gul; Hamid Saeed; Zikria Saleem; Fawad Rasool; Furqan Kurshid Hashmi; Muhammad Islam; Imran Imran; Syed Atif Raza; Zeeshan Danish
Journal:  BMC Med Ethics       Date:  2021-01-04       Impact factor: 2.652

Review 6.  Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics.

Authors:  Rosa Terracciano; Mariaimmacolata Preianò; Annalisa Fregola; Corrado Pelaia; Tiziana Montalcini; Rocco Savino
Journal:  Int J Mol Sci       Date:  2021-01-07       Impact factor: 5.923

7.  Evaluation of Medication Package Inserts in Ethiopia.

Authors:  Haftom Gebregergs Hailu; Mengistie Yirsaw Gobezie; Khalid Beshir Tuem; Hildana Tewolde Gebremichael; Solomon Ahmed Mohammed
Journal:  J Environ Public Health       Date:  2022-01-19

8.  Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis.

Authors:  Jagadeswara Rao Earla; George J Hutton; J Douglas Thornton; Hua Chen; Michael L Johnson; Rajender R Aparasu
Journal:  Explor Res Clin Soc Pharm       Date:  2021-05-05

9.  Development of a Definition for Medical Affairs Using the Jandhyala Method for Observing Consensus Opinion Among Medical Affairs Pharmaceutical Physicians.

Authors:  Ravi Jandhyala
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.